S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:FBRX

Forte Biosciences - FBRX Stock Forecast, Price & News

$1.33
+0.04 (+3.10%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.27
$1.35
50-Day Range
$1.15
$1.53
52-Week Range
$1.03
$5.95
Volume
77,487 shs
Average Volume
379,017 shs
Market Capitalization
$19.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Forte Biosciences MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.19mentions of Forte Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.77) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.42 out of 5 stars

Medical Sector

1068th out of 1,135 stocks

Pharmaceutical Preparations Industry

524th out of 557 stocks

FBRX stock logo

About Forte Biosciences (NASDAQ:FBRX) Stock

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Forte Biosciences Price Performance

Forte Biosciences stock opened at $1.33 on Friday. Forte Biosciences has a 1 year low of $1.03 and a 1 year high of $5.95. The firm has a 50-day moving average of $1.27 and a two-hundred day moving average of $1.33.

Forte Biosciences (NASDAQ:FBRX - Get Rating) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.17) earnings per share for the quarter. Equities analysts forecast that Forte Biosciences will post -0.77 EPS for the current fiscal year.

Receive FBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter.

FBRX Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Forte Biosciences GAAP EPS of -$0.17
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Forte Trials Falters, Stock Punished
Forte Biosciences Inc.
There Isn't Any Good Speculative Stock Picking Right Now
See More Headlines
Receive FBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter.

FBRX Company Calendar

Last Earnings
5/16/2022
Today
8/14/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FBRX
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Net Income
$-21,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$40,000.00
Book Value
$2.82 per share

Miscellaneous

Free Float
13,207,000
Market Cap
$19.63 million
Optionable
Not Optionable
Beta
0.79














FBRX Stock - Frequently Asked Questions

Should I buy or sell Forte Biosciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last twelve months. There are currently 1 sell rating and 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FBRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FBRX, but not buy additional shares or sell existing shares.
View FBRX analyst ratings
or view top-rated stocks.

How have FBRX shares performed in 2022?

Forte Biosciences' stock was trading at $2.14 at the start of the year. Since then, FBRX shares have decreased by 37.9% and is now trading at $1.33.
View the best growth stocks for 2022 here
.

When is Forte Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our FBRX earnings forecast
.

How were Forte Biosciences' earnings last quarter?

Forte Biosciences, Inc. (NASDAQ:FBRX) released its earnings results on Monday, May, 16th. The company reported ($0.17) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Forte Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), electroCore (ECOR), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN).

What is Forte Biosciences' stock symbol?

Forte Biosciences trades on the NASDAQ under the ticker symbol "FBRX."

Who are Forte Biosciences' major shareholders?

Forte Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.47%), Northern Trust Corp (0.13%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Forte Biosciences?

Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Forte Biosciences' stock price today?

One share of FBRX stock can currently be purchased for approximately $1.33.

How much money does Forte Biosciences make?

Forte Biosciences (NASDAQ:FBRX) has a market capitalization of $19.63 million and generates $40,000.00 in revenue each year.

How can I contact Forte Biosciences?

Forte Biosciences' mailing address is 1124 W CARSON STREET MRL BUILDING 3-320, TORRANCE CA, 90502. The official website for the company is www.fortebiorx.com. The company can be reached via phone at (310) 618-6994 or via email at investors@fortebiorx.com.

This page (NASDAQ:FBRX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.